Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about NVO stock here.

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...

Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

According to DataM Intelligence, the Glucagon-like Peptide-1 (GLP-1) Analogues Market is witnessing a transformative expansion, driven by soaring demand for effective obesity management and type 2 ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

According to DataM Intelligence, the Glucagon-like Peptide-1 (GLP-1) Analogues Market is witnessing a transformative expansion, ...

A groundbreaking study has compared the three top weight loss medications on the market, which has produced some surprising ...